您好, 歡迎來到化工儀器網(wǎng)! 登錄| 免費注冊| 產(chǎn)品展廳| 收藏商鋪|
BioXcell熱銷產(chǎn)品推薦--InVivoPlus anti-mouse PD-L1 (B7-H1)
產(chǎn)品描述:
BioXcell InVivoPlus anti-mouse PD-L1 10F.9G2單克隆抗體與小鼠PD-L1(也稱為B7-H1或CD274)反應(yīng)。PD-L1是屬于Ig超家族的B7家族的I型跨膜蛋白,分子量為40kDa。PD-L1在T淋巴細胞、B淋巴細胞、NK細胞、樹突狀細胞以及IFNγ刺激的單核細胞、上皮細胞和內(nèi)皮細胞上表達。PD-L1與CD4和CD8胸腺細胞以及活化的T和B淋巴細胞和骨髓細胞上的受體PD-1結(jié)合。PD-L1與PD-1的結(jié)合導(dǎo)致抑制TCR介導(dǎo)的T細胞增殖和細胞因子產(chǎn)生。PD-L1被認為在腫瘤免疫逃逸中起著重要作用。誘導(dǎo)的PD-L1表達在許多腫瘤中很常見,并導(dǎo)致腫瘤細胞對CD8 T細胞介導(dǎo)的裂解的抗性增加。在黑色素瘤的小鼠模型中,可以通過用阻斷PD-L1和PD-1之間相互作用的抗體進行治療,暫時抑制腫瘤生長。10F.9G2抗體已被證明可以阻斷PD-L1和PD-1之間以及PD-L1和B7-1之間的相互作用(CD80)。
產(chǎn)品詳情:
產(chǎn)品名稱 | InVivoPlus anti-mouse PD-L1 (B7-H1) |
產(chǎn)品貨號 | BP0101 |
產(chǎn)品規(guī)格 | 5/25/50/100mg |
反應(yīng)種屬 | Mouse |
克隆號 | 10F.9G2 |
同種型 | Rat IgG2b, κ |
免疫原 | Mouse CD274 |
實驗應(yīng)用 | in vivo PD-L1 blockade |
產(chǎn)品形式 | PBS, pH 6.5,Contains no stabilizers or preservatives |
純度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
無菌處理 | 0.2 µm filtration |
純化方式 | Protein G |
RRID | AB_10949073 |
分子量 | 150 kDa |
小鼠病原檢測 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存條件 | 抗體原液保存在4°C,不能冷凍保存。 |
推薦同型對照 | InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin(貨號BP0090) |
推薦抗體稀釋液 | InVivoPure pH 6.5 Dilution Buffer(貨號IP0065) |
為什么選擇InVivoPlus抗體?
InVivoPlus級別的產(chǎn)品內(nèi)毒素含量更低,經(jīng)過多種實驗驗證,更適合用于體內(nèi)實驗研究
該產(chǎn)品自上市已被多篇SCI文獻引用,品質(zhì)有保證,以下是部分已發(fā)表的文獻引用:
應(yīng)用 | 文章 |
體內(nèi)PD-L1阻斷 (in vivo PD-L1 blockade) | 1. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100. 2. Stathopoulou, C., et al. (2018). 'PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells' Immunity 49(2): 247-263 e247. 3. Kim, J., et al. (2015). 'Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help' Nat Commun 6: 7994. |
體內(nèi)PD-L1阻斷,流式細胞術(shù) (in vivo PD-L1 blockade, Flow Cytometry) | 1. Aloulou, M., et al. (2016). 'Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells' Nat Commun 7: 10579. 2. Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811. 3. Rutigliano, J. A., et al. (2014). 'Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells' J Virol 88(3): 1636-1651. |
體內(nèi)PD-L1阻斷,免疫熒光 (in vivo PD-L1 blockade, Immunofluorescence) | 1.Willimsky, G., et al. (2013). 'Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance' J Clin Invest 123(3): 1032-1043. |
免疫組織化學(xué)(冷凍切片),免疫熒光 (Immunohistochemistry (frozen), Immunofluorescence) | 1.Riella, L. V., et al. (2011). 'Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts' Am J Transplant 11(4): 832-840. |
更多產(chǎn)品詳情請聯(lián)系 BioXcell 中國授權(quán)代理——欣博盛生物
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實性、準確性和合法性由相關(guān)企業(yè)負責(zé),化工儀器網(wǎng)對此不承擔(dān)任何保證責(zé)任。
溫馨提示:為規(guī)避購買風(fēng)險,建議您在購買產(chǎn)品前務(wù)必確認供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。